Understanding Cancer Heterogeneity Could Further Reduce Chemo Use, Says Expert

Credit: Antonio Giordano

“Understanding cancer heterogeneity could further reduce chemo use,” says cancer research expert Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University. “Further study of cases that can successfully be treated with hormone- and immunotherapy, and how to identify them, will unlock this potential.”

Giordano refers to the TAILORx study, published by The New England Journal of Medicine this week, which describes treatment outcomes in breast cancer comparing cases receiving both endocrine therapy and chemotherapy, versus those receiving only endocrine therapy. Under certain conditions, including the early-stage development of tumor size, and the tumor not having spread to any peripheral lymph nodes, endocrine therapy alone resulted in nearly identical rates of survival and recurrence as endocrine- and chemotherapy combined.

“It is important to underscore that this specific study refers to patients with small tumors and no lymph node infiltrations,” says Giordano. “Women with early-stage breast cancer may be able to avoid chemotherapy, which is exciting, because there are pros and cons associated with it. The treatments have unavoidable effects on healthy cells as well as cancer cells”

“The goal of precision medicine moving forward,” Giordano says, “is to identify more sophisticated approaches to this problem of cancer heterogeneity. Every type of cancer, at the molecular level, can have a cell environment that changes and evolves through the course of the disease. Or from patient to patient.”

“Only by understanding specific targets or molecules responsible for key cellular processes will we be able to understand, with precision, new options of therapeutic target that could replace chemotherapy altogether,” Giordano says.

“The precision target is not yet precise enough,” Giordano says. “But the option to spare many patients the potential harmful effects of chemo is a sign we are moving in the right direction.”

Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University and Professor of Pathology at the University of Siena, Italy.

In 1993, Antonio Giordano, M.D., Ph.D., founded the Sbarro Institute with a generous donation from Mario Sbarro, the Founder of the Sbarro restaurant chain, following Dr. Giordano’s discovery of the tumor suppressor gene pRb2.

About Sbarro Health Research Organization

Sbarro Health Research Organization conducts research in cancer, diabetes, and cardiovascular disease. Based in Philadelphia, Pennsylvania on the campus of Temple University, our programs train young scientists from around the globe.

Original Newswise Posting                         PubMed Abstract

In Debate of Scheduled Versus Spontaneous Exercise, Which Motivates You More?

Older adults seem to be more motivated by scheduled workouts, including the role of a fitness coach or a significant person involved in their exercise goals, when compared to those getting exercise only through spontaneous physical activity.

Researchers tested a mathematical and psychological model on two different samples of older adults: the first doing spontaneous physical activity, the second engaged in an exercise class. This theoretical model tried to understand what is really important to  encourage and maintain the intention to do physical activity.

The results suggest a psychological construct called autonomous motivation, in which subjects experience a sensation of value and self-worth tied to the activities. Participants that felt a sense of autonomous motivation during an exercise program were more successful at beginning and maintaining a more healthy, active lifestyle, despite possible interruptions caused by physical discomfort or scheduling challenges.

The researchers published their findings in the journal Gerotarget, a section of Oncotarget. Psychologists from the faculty of Medicine and Psychology of Sapienza, University of Rome, led by Prof. Fabio Lucidi, partnered with the American research team of Prof. Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, and University of Siena, Italy to produce the study.

The aging of the world’s population is a steadily growing phenomenon, with the older adult population expected to triple by the year 2050. Therefore, taking care of older adults is considered an important social goal. Physical activity and exercise are two behaviors that may prevent diseases, cognitive decline, and loneliness among older adults. Despite the well-established positive effects of physical activity and exercise, data shows that few older adults are engaged in these behaviors.

“This study,” explains first author Federica Galli, “shows clearly that the sensation autonomous motivation leads older adults to be successful implementing these healthy behaviors.”

“Thanks to the new therapies produced by oncological research, a lot of patients with oncological diseases will be able to live normal life expectancies,” Giordano adds. “For this reason, it’s very important to study the mechanisms to motivate people to exercise, given the therapeutic role of fitness and physical activity in oncological diseases.”

The study provides guidelines for professionals that work in preventive medicine in the older population, so that they can support the perception of autonomy that could increase their motivation to start and maintain physical activity and exercise.

“The NCI of Naples has always been sensitive to this issue,” says Scientific Director of the National Cancer Institute of Naples, Gerardo Botti. “In the future, I am already  considering the implementation of new studies that would consider the application of this model to target populations more at risk such as our oncology patients,” Botti says.

 

Original Newswise Posting

Molecular Inhibitors Can Boost Natural Tumor Suppression to Fight Lung Cancer and Mesothelioma

Inhibition of the oncogenic kinase AKT, a key protein governing the cell cycle, was found to arrest cancer cell proliferation and triggered their programmed death by apoptosis. The study, published today in Oncogene, represents significant progress in the clinical translation of previous basic scientific discoveries.

“Understanding the molecular features that govern cancer cell behavior is the basis for the design of the so-called ‘targeted therapies’ which constitute modern precision medicine,” says senior author on the paper Antonio Giordano, M.D., Ph.D., director of the Sbarro Health Research Organization at Temple University.

The study revealed an important role of the cell cycle protein RBL2/p130 in triggering cancer cell death upon inhibition of AKT, which is hyperactive in many cancer types. The researchers found that RBL2/p130, a known tumor suppressor factor isolated by Giordano himself in the 1990s, is a direct target of the AKT kinase. The pharmacological inhibition of AKT led to RBL2/p130 protein stabilization, in both lung cancer and mesothelioma cell lines, and favored its localization to the cell nucleus, where it can function restricting cell proliferation, a well defined function of RBL2/p130 and of the other retinoblastoma proteins belonging to its family.

Further confirming the crucial role of RBL2/p130 in determining the cell response to AKT inhibition, the authors showed that AKT pharmacological inactivation no longer caused cancer cell death when RBL2/p130 expression was shut down through a specific silencing. Conversely, RBL2/p130 re-expression in previously silenced cells restored cell ability to undergo programmed death following AKT kinase inhibition.

AKT is a recognized target for antitumor strategies owing to its high levels in multiple tumors, and the manner in which it stimulates oncogenic pathways. Therefore, many companies have developed AKT inhibitors which are currently being tested in clinical trials. As RBL2/p130 is crucial in determining cancer cell fate upon AKT kinase inhibition, RBL2/p130 could serve as a predictive factor of the response to such a therapeutic strategy. The authors also assessed whether AKT pharmacological targeting could function in synergy with other approaches aimed at re-activating RBL2/p130 tumor suppressor function. The results confirmed that AKT inhibition functioned in synergy with cyclin dependent kinase (CDK) inhibitors in both preclinical models of lung cancer and mesothelioma. CDKs are the main kinases known to phosphorylate RBL2/p130, restraining its cell cycle-related tumor suppressor function.

“The combined use of these agents, AKT and CDK inhibitors, which converge on RBL2/p130 reactivation and are currently being investigated in the clinical setting, could help to reduce their dosage and consequently their associated toxicities,” says lead author Francesca Pentimalli of the National Cancer Institute of Naples Pascale Foundation, CROM.

“Our findings were conducted in lung cancer and mesothelioma, the latter being a tumor caused by exposure to asbestos, against which no curative approach exists,” says Giordano.  “However, given that RBL2/p130 is rarely mutated in cancer, but rather is mostly inactive by the action of AKT and CDK kinases, it is likely that this therapeutic strategy could work in a wider variety of tumors.”

The study, which was funded by the Italian Association for Cancer Research, the Sbarro Health Research Organization and the Mesothelioma Applied Research Foundation, stemmed from a productive collaboration between the University of Siena and the National Cancer Institute of Naples Pascale Foundation, CROM.

Original Newswise Release         PubMed Abstract

Virtual Reality: An Escape From Painful and Stressful Medical Treatments

Virtual reality (VR) technology allows users to immerse themselves in a three-dimensional computer-generated world, and despite being originally developed as an entertainment tool, over the last two decades VR has found a variety of applications in health care. Among these applications, which include treatment of phobias and anxiety disorders; cognitive and physical rehabilitation; pain management; treatment of eating disorders and obesity; surgical training and aid in surgical planning and performance, VR has shown promise in several clinical trials assessing its possible utility as a distraction tool to alleviate pain and distress during medical procedures.

A review article, recently published in The Clinical Journal of Pain, provides a comprehensive overview of the clinical studies using VR during several painful and stressful medical procedures, including burn injury treatments, chemotherapy, surgery, dental treatment, and other diagnostic and therapeutic procedures.

“VR has proven to be very effective in relieving pain, even in patients subjected to extremely painful procedures, who do not receive proper relief with pharmacological treatments alone,” says Antonio Giordano, M.D., Ph.D., of the Sbarro Health Research Organization at Temple University, and University of Siena, Italy, and corresponding author of the article. “Moreover, VR decreases cancer-related symptoms in different settings, including during chemotherapy. This is remarkable, considering that identifying interventions able to enhance treatment tolerance is crucial to improve both patients’ quality of life and compliance to therapies, which, in turn, can increase their chances of recovery.”

“Despite these promising results, we wanted to point out that further studies involving a greater number of patients are needed both to generalize the observations and to establish predictive factors to select patients who are more likely to benefit from VR,”  says study author Paola Indovina of the Institute for High Performance Computing and Networking, ICAR-CNR, Naples. “Moreover, more efforts should be put into the evaluation of changes in physiological factors, which might provide objective confirmations of the patients’ self-report measures. Also, more studies should explore VR efficacy after several repeated sessions to assess possible long-term benefits of the VR intervention.”

“It is also important to note that most studies so far used relatively low-tech VR systems compared to the state-of-the-art systems available on the market today, which are more immersive, more user-friendly, more portable, and much less expensive,” adds coauthor Giuseppe De Pietro, Director of the Institute for High Performance Computing and Networking, ICAR-CNR, Naples, Italy. “Therefore, VR has the potential both to become more effective and to find a more widespread use.”

Journal Reference:

Indovina P, Barone D, Gallo L, Chirico A, De Pietro G, Giordano A. Virtual reality as a distraction intervention to relieve pain and distress during medical procedures: a comprehensive literature review. Clin J Pain, 2018.

Original Newswise Release

Repurposed Parasite Drug New Weapon Against Mesothelioma

Anthelmintic drug already approved to treat infections of pinworm parasite was shown to effectively impair both mesothelioma cell growth and migration.

Mesothelioma, a very aggressive cancer, is mainly associated with exposure to asbestos. No effective therapies are currently available to treat mesothelioma, and the prognosis is extremely poor. Therefore, there is an urgent need to identify new possible therapeutic approaches.

Researchers challenged mesothelioma cells with pyrvinium pamoate, testing the potential to repurpose a drug already approved to treat infections of pinworm parasite. Analyzing at the molecular level, researchers found that the drug affected the expression of downstream genes in the WNT signaling pathway, which are implicated in mesothelioma aggressiveness and its resistance to conventional therapy.

Published in the Journal of Cell Physiology, the study was conducted by research groups lead by Dr. Antonio Giordano at the Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, with collaborators at the University of Siena, Italy.

“These are encouraging results, especially considering that drug repositioning, using already approved drugs for new indications, is a promising strategy to identify active molecules for a more rapid and less expensive clinical translation compared to de novo drug development,” says study author Marcella Barbarino of the University of Siena.

“The results of this study represent a step forward in the development of new treatments for patients with mesothelioma. Pyrvinium pamoate is able to affect important features of mesothelioma aggressiveness, suggesting that the repurposing of this drug for mesothelioma treatment could represent a new promising therapeutic approach,” says Giordano.

The study was funded by the Sbarro Health Research Organization (SHRO) and the Mesothelioma Applied Research Foundation, and is dedicated to the memory of Mr. Vittorio Stortino.

Journal Reference: Barbarino M, Cesari D, Intruglio R, Indovina P, Namargedi A, Bertolino FM, Bottaro ME, Delaram R, Bellan C, Giordano A. Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: a pre-clinical assessment. J Cell Physiol, 2018.

 Original Newswise Release                            PubMed Abstract

 

Diverse Role of CDK9 Gene in Cell Regulation Continues to Reveal Cancer Treatment Targets 25 Years After Discovery

This slideshow requires JavaScript.

A gene discovered by Temple University researchers has proved to be an important target for cancer therapy, with the discovery of its roles in controlling cell proliferation, differentiation, apoptosis, and DNA repair. The mutli-functional kinase CDK9 (cyclin-dependent kinase 9) is considered a relatively tractable target for drug discovery and provides a route for the indirect targeting of other gene expression, such as MCL-1 and MYC, which themselves are implicated in cancer progression but are more challenging targets for drug discovery.

“If CDK9 is inhibited or blocked,” says Antonio Giordano, M.D., Ph.D., “it prevents the promotion of differentiation, suggesting that the inhibition of CDK9 leads to selective down-regulation of cell survival genes controlled by super enhancers such as MCL-1, MYC, and cyclin D1.”

The gene for CDK9 was first discovered by Giordano in 1994, the first of many studies of CDK9 developed at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia. Over the past 25 years, CDK9 has proven to play many different roles. As discussed in a review published last week in the Journal of Experimental and Clinical Cancer Research, the functions of CDK9 include cellular differentiation, controlling processes such as transcription, balancing the process of cellular differentiation and apoptosis (programmed cell death), as well as regulating transcription of human immunodeficiencty virus (HIV), all of which suggests potential for targeting this kinase in cancer therapy to control or block key cellular processes.

To thoroughly assess the potential to leverage these multiple functions for combination therapies with CDK9, a variety of inhibitors have been investigated in preclinical and clinical studies. Results have demonstrated antiapoptotic and antitumor effects.

“This is important from a clinical point of view,” says Giordano, Director of the Sbarro Institute, where he is actively investigating the role of CDK9 inhibitors as therapeutics for a variety of hematologic cancers and solid tumors. Based on the body of research describing the role of CDK9 in acute myeloid leukemia (AML), Dr. Giordano suggests that, “targeting the CDK9 pathway, which is dysregulated in AML, is a very attractive approach.”

“Many studies demonstrate that dysregulation of the CDK9 pathway has been observed in human tumors such as lymphoma, prostate cancer, neuroblastoma and others,” says Dr. Silvia Boffo, PhD, research assistant professor at the Sbarro Institute, “and the CDK9-related pathway has emerged as a prioritized target for cancer therapy across a range of different tumor types.”

An immunologic role for CDK9 has also been discovered and was reported in Oncogene by Dr. Giordano, in collaboration with researchers at the University of Siena in Italy. They have shown that it interacts with gp130, the receptor of the Interleukin-6 (IL-6) family of cytokines. “This should allow us to take advantage of IL-6 as therapeutic agents for targeted therapy in selected histotypes of human cancer,” Giordano says.

“As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety,” concludes Dr. Giordano.

Original Newswise release         Pubmed Abstract

How Fluctuations in Sex Hormones Impact AMD

MDMag — The pathogenesis of conditions of the eye such as age-related macular degeneration (AMD) could be impacted by gender-based differences in hormone fluctuations.

Newly published data from a team of investigators from Temple University’s Sbarro Institute has found that variations in sex steroid homeostasis have an effect on the physiology of human male retinal-pigment epithelial cells (RPEs), which are impacted by the inflammation caused by AMD.

According to the authors, the data from this study show high clinical significance as it considers these steroid fluctuations as the prompters of locale changes in the retina. These changes then are able to impact the pathological situation that occur along with aging in the non-reproductive systems—like the eye.

“The main goal of our investigation was to define whether male gender can be considered a risk factor in developing age-related retinal disease including AMD,” Antonio Giordano, MD, PhD, the director of the Sbarro Institute at Temple University, and lead author, told MD Magazine. “Estrogens have historically been associated with women’s physiology, however, over the last 2 decades, several studies have shown that these hormones play a fundamental role in men.”

The pathogenesis of AMD is still not understood despite intense clinical research, although there has been a link, while controversial, found between AMD and gender—more specifically, the effects on RPEs when exposed habitually to estradiol, a reproductive hormone which aids in treating the symptoms caused by menopause, and progesterone, often used to aid in the treatment of uterine changes for post-menopausal women.

“To mimic sex steroid hormone fluctuations occurring with aging, we exposed retinal pigment epithelial cells, ARPE-19, to acute, prolonged or chronic estradiol and progesterone challenges,” Carlo Astarita, PhD, from the University of Siena and a researcher at Temple, as well as coauthor of the study, said in a statement.

Astarita noted that the researchers found that chronic estradiol treatment resulted in RPE cell death via necrosis, occurring due to mechanisms involving the subcellular localization of the retinoblastoma-related protein pRb2/p130 and the extracellular plasminogen activator inhibitor type-2 (PAI-2).

Conversely, the study revealed that chronic exposure to progesterone caused the nuclear subcellular rearrangement and co-immunolocalization of pRb2/p130 with PAI-2. Additionally, it induced the accumulation of cells in the G2/M phase, and a subsequent reduction in necrosis and a surge in apoptosis.

“Today, the mechanisms governing the action of sex steroid hormones in maintaining the health of the eye are still largely unknown and our investigation offers the unique opportunity to unravel the effects of sex hormones,” Mina Massaro-Giordano, MD, a co-author of the study and professor of Ophthalmology at the Hospital of the University of Pennsylvania, said. “Not only in determining gender differences, but also in affecting the physiology of non-reproductive systems, such as the eye.”

“The biology underlying gender-related circumstances should be considered by the clinicians involved in the treatment of eye conditions such as AMD,” Giordano added.

The study’s findings had implication for the transgender community as well, a community that Giordano referred to as “underserved.”

“Exogenous administration of physiologically significant amounts of sex hormones for long periods of time is a common clinical practice for transgender patients seeking sex reassignment,” he said.

The study received funding in part from a grant from the Ken and Ann Douglas Charitable Foundation and the Sbarro Health Research Organization (SHRO).

The study, “Effect of sex steroid hormone fluctuations in the pathophysiology of male- retinal pigment epithelial cells,” was published in the Journal of Cellular Physiology.

Copied from MDMag post          PubMed Abstract      Article at Journal of Cellular Physiology

Cancer DNA Sequencing Has Potential, but Not a Magic Bullet, Says Expert

A recent report by NPR science writer Richard Harris explores the efficacy of DNA sequencing in the treatment of cancer. Antonio Giordano, MD, PhD, President of the Sbarro Health Research Organization (SHRO) at Temple University comments on the potential, and the shortfalls, of this strategy in both the clinical and research setting.

“Only a few of the genetic mutations that occur in cancer actually act as ‘drivers’ to tumor malignancy,” Giordano says. “Most act simply as ‘passengers’ in the tumor.”

“This makes finding a genetic target for treatment like finding a needle in a haystack,” says Giordano.

With research focused on cell cycle mechanisms for over 30 years, Giordano’s work has often concentrated on the impact that genetic mutation has on natural cellular processes and the subsequent effect on the growth and spread of cancer.

“We have identified proteins which act as the engine of the cells, such as the cyclin-dependent kinases, as well as a key member of the retinoblastoma family of tumor suppressors which act as the ‘brakes’ on tumor growth,” says Giordano. “Based on this fundamental knowledge, with my collaborator Dr Francesca Pentimalli, we are currently developing strategies that can specifically target these mechanisms in cancer cells.”

“Many therapies are aimed at inhibiting active oncogenes, often identified through DNA sequencing,” Giordano says. “Alternatively, we are testing drugs designed to restore the body’s natural ability of the retinoblastoma protein RBL2/p130 to suppress cancer.”

“We predict this will be successful in treating cancer types in which the RBL2/p130 ability to inhibit tumor growth is suppressed by other oncogenic pathways, rather than mutated itself,” says Giordano.

The major difficulty in using DNA sequencing to identify a treatment target, Dr. Giordano says, lies in the heterogeneic nature of tumors.

“No tumor is identical to another from the molecular point of view, and, even a tumor from a single individual changes over time. Subpopulations and mutations occur as the tumor develops, through progression, and after it is challenged therapeutically,” Giordano says.

“This often renders DNA sequencing insufficient on its own to capture the complexity of tumour cells’ genetic machinery. Eventually the tumour microenvironment affects the stability and function of the protein coded by DNA and can ‘muddy the water’ when it comes to identifying a single genetic treatment target,” says Giordano.

“Fortunately, many alterations in cancer affect a limited number of cancer signalling pathways, and we already have therapeutic tools for many of these targeted genes in our anticancer drug arsenal,” Giordano says.

Lastly, Giordano believes more emphasis should be placed on effective communication of scientific breakthroughs to doctors and patients.

“Cancer DNA sequencing, and even other types of profiling, can be very informative,” says Giordano, “but the main hurdle is the cost-effectiveness of these approaches which cannot be routinely used in the clinical practice.”

“For example, late mutation can occur during the natural progress of tumor growth, and these sometimes act as a marker of resistance to treatment,” says Giordano. ”Similar to the story on NPR about Ben Stern, a patient in which a previously treated tumor had grown back, doctors and patients should consider the timing and signs of when DNA sequencing may offer a solution.”

“But sensational announcements should be avoided,” cautions Giordano, “and clinicians should avoid looking to DNA sequencing as a ‘magic bullet.’”

“The winning recipe must be to build on step-by-step achievements of research aimed at the same target: to improve the survival of patients with cancer,” Giordano concludes.

Original Newswise Release

Detecting Pompe Disease with More Accuracy Key to Urgent Intervention

Credit: Sbarro Health Research Organization (SHRO)
“Vacuolated PAS positive lymphocytes in the peripheral blood of Pompe patients”

Researchers identified a new, more sensitive screening test to recognize Pompe disease, a metabolic disorder affecting cellular processing of glycogen in numerous tissues of the body. The test detects the presence of more than four lymphocytes containing glycogen in blood films of subjects with suspicious neuromuscular disease, and has demonstrated 100% sensitivity and 94% specificity identifying patients with Pompe disease. Moreover, positivity of vacuolated lymphocytes to the Periodic-Acid Schiff staining (PAS) seems to be an hallmark of autophagic myopathies. This new method of detection will allow clinicians to differentiate Pompe disease and autophagic myopathies from other neuromuscular disorders more accurately.

The study was published online in December 2017, in the Journal of Cellular Physiology.

Pompe disease, also known as Glycogen storage disease type II, is a metabolic disorder caused by an accumulation of glycogen in the lysosomes due to a deficiency of alpha-glucosidase, a lysosomal enzyme acid. The build-up of glycogen affects various body tissues, particularly heart, skeletal and respiratory muscles, as well as lymphocytes in peripheral blood. The classic infantile form of Pompe disease, presenting with marked generalized muscle weakness and severe hypertrophic cardiomyopathy, rapidly progresses to a fatal outcome. The late-onset form is characterized by slowly progressive myopathy involving proximal, limb-girdle, paraspinal, and respiratory muscles without cardiac involvement. Vacuolar myopathy typical of Pompe disease is the most frequent myopathy due to an impairment of autophagy, the main natural mechanism necessary to degrade and recycle cellular components.

Enzyme replacement therapy for Pompe disease became available in 2006 and resulted in dramatic reduction of mortality and morbidity for Pompe patients. The discovery and commercialization of this therapy figure prominently in the plot of the 2010 film “Extraordinary Measures,” starring Harrison Ford and Brendan Fraser. Since an early start of therapy is associated with better clinical outcomes, early diagnosis is essential in order to achieve the maximum benefit.

The research was conducted by a team of scientists lead by Dr. Simone Sampaolo and Mariarosa AB Melone, Department of  Medicine, Surgery, Neurology, Metabolic and Aging Science, Reference Center for Neurological and Neuromuscular Rare Disease, University of Campania “Luigi Vanvitelli”, Naples, in collaboration with Dr. Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Department of Biology at Temple University, Philadelphia.

Pompe disease is an underdiagnosed disorder, and considering that therapy is now available, early diagnosis is crucial to obtain the best prognosis. This research proposes a reliable, cheap, simple, first-level screening method to support the diagnosis of autophagic vacuolar myopathy as Pompe disease. The test is minimally invasive and could be used as a screening test in high-risk populations, such as pregnant women and people with a family history of neuromuscular disorders.

Newswise Original Release         PubMed Abstract     Journal of Cellular Physiology

Celebrating Our Women’s Research Team!

At S.H.R.O. we are so proud of the remarkable advances our researchers are contributing to the field of medical research.

Members of our Women’s Research Team are currently studying mechanisms contributing to breast, lung, ovarian, and colon cancer.

GoFundMe to Benefit our Women-Led Research Initiatives and Professional Advances

This month to celebrate our women scientists we are launching a GoFundMe campaign where all proceeds will go towards women-led research projects and further medical education aimed at curing and diagnosing cancer.

DONATE TO SUPPORT OUR WOMEN SCIENTISTS TODAY!   

 

Scientist of the Month

Congratulations Mia Robb, Future Dr. Robb and Scientist of the Month!

We are very happy to announce that our scientist Mia Robb was just accepted into PCOM’s medical class of 2018! Mia has worked at S.H.R.O. for the last 9 years and we are so proud of her continued commitment to the field.

As part of our GoFundMe campaign this month we will be donating 25% of all proceeds raised to begin a scholarship fund for Mia’s medical school.